A bitter pill or miracle cure? The drive towards the restructuring of UK pharmaceutical distribution
Opportunity for pharma to reduce counterfeiting and improve comparative advantage through exclusive distribution.
- File size:
1.06 MB - Published on:
2007-07-31 03:51 PM
A Thought Leadership piece that explores the rationale behind the recent move towards exclusive distribution in the pharmaceutical industry, as exemplified by Pfizer and AstraZeneca.
Capgemini believes that exclusive distribution has the potential to combat counterfeit drug entry into the supply chain and provides the required control over pricing for big pharma to regain price parity with parallel imports.
Please sign-in to download the document.
No account? Register with us!
